Skip to main content

University of Maryland Medicine Tests Novel Treatment for Parkinson's

September 01, 2015 | David Kohn

Howard M. Eisenberg, MD

Metabolic Imaging Center Uses New Ultrasound Technology to Target Deep Structures of the Brain

University of Maryland Medicine (the University of Maryland Medical Center and the University of Maryland School of Medicine) and its Center for Metabolic Imaging and Image-Guided Therapeutics (CMIT) has begun to use MRI-guided focused ultrasound on a deep structure within the brain related to Parkinson’s disease – the globus pallidus.

In the first clinical trial of its kind, researchers from the Departments of Diagnostic Radiology & Nuclear Medicine, Neurosurgery and Neurology at CMIT are using magnetic resonance imaging (MRI) to guide ultrasound waves through the intact skin and skull to the globus pallidus. The University of Maryland is one of only two sites in the United States to offer this treatment to Parkinson’s patients.

The globus pallidus contributes to the regulation of voluntary movements and is targeted with medications and, in advanced cases, deep brain stimulation using implanted micro-electrodes to treat motor symptoms of tremor, rigidity and dyskinesia in patients with Parkinson’s. Dyskinesia (abnormal, distorted movement) is a common side effect of the medication levodopa that can affect quality of life for patients with Parkinson’s.

“In collaboration with my colleagues, we are excited to offer our patients a new, non-invasive therapy to control their Parkinson’s symptoms,” said principal investigator Howard M. Eisenberg, MD, the Raymond K. Thompson Chair of Neurosurgery. “The neurology community has made significant strides in helping patients with Parkinson’s over the years; utilization of MRI-guided focused ultrasound could help limit the life-altering side effects like dyskinesia to make the disease more manageable and less debilitating.”

CMIT, under the direction of Rao Gullapalli, PhD, MBA, Professor of Diagnostic Radiology & Nuclear Medicine, is a collaborative venture between University of Maryland Medicine and industry partners, with the goal to explore, promote, innovate and create imaging technologies for efficient translation from “bench to bedside” and, ultimately, to serve as an inter-disciplinary “hub” of collaboration and innovation for engineering, physical sciences and medicine. The Medical Director for CMIT is Dheeraj Gandhi, MBBS, Professor of Diagnostic Radiology & Nuclear Medicine.

“For years, our medical techniques have centered around anatomic imaging of the body and open surgical techniques to repair structural problems,” said Graeme Woodworth, MD, Associate Professor of Neurosurgery and Director of the Neurosurgery Department’s Translational Research Laboratory. “CMIT is set to move this paradigm toward imaging body function and modifying alterations using non-invasive, image-guided focused ultrasound technology. We are very excited that these new technologies, available at the University of Maryland, are on course to revolutionize medical diagnosis and treatment,” he said.

According to Dr. Woodworth, examples of this work leverage altered metabolic pathways to visualize disease processes and treatment responses, providing new information regarding the course of a patient's condition. Using advanced focused ultrasound technology, surgeons can now apply microscopic sound waves to precisely target diseased regions deep within the body without incisions or radiation.

Functional imaging and non-invasive ultrasound procedures are done on an outpatient basis in the CMIT MRI suite. During the Parkinson’s procedure, patients lie in an MRI scanner with a head-immobilizing frame fitted with a transducer helmet. Ultrasonic energy is targeted through the skull to the globus pallidus of the brain, and images acquired during the procedure give physicians a real-time map of the area being treated.

“We’re raising the temperature in a very restricted area of the brain to destroy tissue,” Dr. Eisenberg said. “The ultrasound waves create a heat lesion that we can monitor through MRI.”

The entire procedure lasts two to four hours, and patients are awake and able to interact with the treatment team. This allows the physicians to monitor the immediate effects of treatment and make adjustments if necessary.

“Treatment-related side effects such as dyskinesia are the main reason my patients undergo surgery,” added Paul S. Fishman, MD, PhD, Professor of Neurology and sub-investigator on the clinical trial. “Focused ultrasound could offer these patients an alternative to surgery.”

The clinical study builds on experience gained during a pilot trial that investigated focused ultrasound for patients with essential tremor. The University of Maryland Medical Center (UMMC) was one of eight sites that participated in the pivotal Phase III trial to support a submission to the FDA for regulatory approval, says site principal investigator Elias R. Melhem, MD, Professor and the Dean John M. Dennis Chairman of the Department of Diagnostic Radiology & Nuclear Medicine. The study continues to enroll patients at UMMC.

“The University of Maryland Parkinson's Disease and Movement Disorders Center has long offered patients access to groundbreaking experimental therapies for Parkinson’s,” said E. Albert Reece, MD, PhD, MBA, Vice President for Medical Affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the School of Medicine. “Our faculty's commitment to finding new treatment options for Parkinson’s patients shows the value of inter-disciplinary work that has potential for treating other critical neorogenerative diseases as well.”

As many as one million Americans have Parkinson’s disease, a chronic, degenerative disorder for which there is no cure. The second most common movement disorder, Parkinson’s results from the malfunction or loss of brain cells crucial for movement and coordination. Symptoms include motor difficulties such as tremor, rigidity and postural instability. People with Parkinson’s can also experience non-motor symptoms of cognitive impairment, depression and anxiety, and autonomic dysfunction.

Essential tremor, which is eight times more common than Parkinson’s disease, causes debilitating shaking that can be resistant to drug therapy. It mainly affects the hands, head and voice, making aspects of daily life like eating, drinking and writing extremely difficult.

Researchers from the University of Virginia Health System reported in the New England Journal of Medicine in 2013 that 15 patients with essential tremor who received focused ultrasound saw “significant improvement” in their dominant hand tremor. Patients treated in the initial phase of the study at the University of Maryland experienced similar results.

The Michael J. Fox Foundation for Parkinson’s Research and the Focused Ultrasound Foundation are funding the Parkinson’s study. It is being conducted using the ExAblate Neuro system developed by INSIGHTEC. Dr. Eisenberg is a consultant to INSIGHTEC.

About the University of Maryland School of Medicine

The University of Maryland School of Medicine, chartered in 1807 as the first public medical school in the United States, continues today as a leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland, and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland’s Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists, plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S., with top-tier faculty and programs in vaccine development, cancer, brain science, surgery and transplantation, trauma and emergency medicine, and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the U.S., but also has a global presence, with research and treatment facilities in more than 35 countries around the world. For more information, visit

About the University of Maryland Medical Center

The University of Maryland Medical Center (UMMC) is comprised of two hospitals in Baltimore: an 800-bed teaching hospital — the flagship institution of the 12-hospital University of Maryland Medical System (UMMS) — and a 200-bed community teaching hospital, UMMC Midtown Campus. UMMC is a national and regional referral center for trauma, cancer care, neurocare, cardiac care, diabetes and endocrinology, women's and children's health, and has one of the largest solid organ transplant programs in the country. All physicians on staff at the flagship hospital are faculty physicians of the University of Maryland School of Medicine. At UMMC Midtown Campus, faculty physicians work alongside community physicians to provide patients with the highest quality care. UMMC Midtown Campus was founded in 1881 and is located one mile away from the University Campus hospital. For more information, visit


Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)

David Kohn
Director of Medicine and Science Communications
University of Maryland School of Medicine
Office of Public Affairs
(410) 706-7590

Related stories

    Monday, February 28, 2022

    UM School of Medicine Research Leads to Innovative Non-Invasive Treatment for Parkinson’s Disease at UM Medical Center

    – A non-invasive ultrasound treatment for Parkinson’s disease that was tested in a pivotal trial led by University of Maryland School of Medicine (UMSOM) researchers is now broadly available at the University of Maryland Medical Center (UMMC). The device, called Exablate Neuro, was approved in November by the US Food and Drug Administration to treat advanced Parkinson’s disease on one side of the brain.

    Wednesday, November 13, 2019

    UM School of Medicine Establishes Endowed Professorship in Neurosurgery Through Private Gifts and Matching State Funds

    University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that the UMSOM has been awarded matching funds from the Maryland E-Nnovation Initiative Fund (MEIF), administered by the Maryland Department of Commerce. The funds, when combined with private philanthropy, will enable UMSOM to establish the Howard M. Eisenberg, MD, Distinguished Professorship in Neurosurgery.

    Thursday, March 28, 2019

    UM School of Medicine Announces Leadership Transition in Department of Neurosurgery

    Dean E Albert Reece, MD, PhD, MBA, announced today that longtime Chair of the Department of Neurosurgery and nationally-recognized neurosurgeon Howard M. Eisenberg, MD, will be stepping down at the end of this academic year as chair after 23 years. He will return to the full-time faculty of the UMSOM Department of Neurosurgery, retaining his title as the R.K. Thompson Professor of Neurosurgery. He will continue his research and his efforts advancing surgical techniques including gamma knife radiosurgery and image-guided focused ultrasound.

    Friday, February 16, 2018

    University of Maryland Medicine Leads Pivotal Study of Focused Ultrasound to Treat Parkinson's Disease

    University of Maryland Medicine (the University of Maryland Medical Center (UMMC) and the University of Maryland School of Medicine (UMSOM)) is leading a phase 3 study to test the safety and efficacy of using MRI-guided focused ultrasound on the brain in order to treat Parkinson’s disease. The pivotal study is the final step before the U.S. Food and Drug Administration (FDA) will consider approving the new technology for widespread use as a nonsurgical treatment option to eliminate key motor symptoms of this common neurological condition.

    Tuesday, August 30, 2016

    New Study Shows Breakthrough Treatment for Essential Tremor Using Focused Ultrasound

    University of Maryland School of Medicine (UM SOM) researchers, along with an international group of investigators, have discovered for the first time that treatment with MRI-guided focused ultrasound can effectively treat patients with essential tremor (ET), a neurological movement disorder that affects an estimated 10 million people in the U.S. The results, which are published in the forthcoming issue of the New England Journal of Medicine, led to recent approval of the treatment by the Food & Drug Administration (FDA),

    Tuesday, May 03, 2016

    UM SOM Identifies Compound That Reverses Symptoms of Alzheimer's and Parkinson's Diseases

    Alzheimer’s and Parkinson’s disease are the two most common neurodegenerative disorders worldwide, and cause untold suffering to millions of patients and their families. Treatments for these diseases are limited, and no cures exist. Now, a new study describes an innovative strategy that reverses symptoms in these neurodegenerative diseases – at least in fruit flies genetically altered to model the diseases.